Markets
markets

D-Wave Quantum posts Q3 revenue beat

D-Wave Quantum reversed its premarket gains despite reporting better-than-expected Q3 sales, and is trading deep in the red minutes after the opening bell sounded.

The quarterly results:

  • Revenue: $3.7 million (compared to an analyst consensus estimate of $3.03 million)

  • Adjusted earnings per share: -$0.05 (estimate: -$0.07)

“Our strong third-quarter results reflect the momentum we see building across every aspect of our business, with key metrics, including revenue, gross profit, bookings, and cash balance, clearly indicating D-Wave’s success in accelerating global quantum computing adoption,” CEO Dr. Alan Baratz said.

D-Wave ended Q3 with $2.4 million in bookings (that is, its pipeline of expected future sales), but said that number has gone up by $12 million since the end of that quarter. Much of that appears to be linked to an agreement with Swiss Quantum Technology to deploy one of its systems.

The prospect of government support has been a major catalyst for the quantum space in recent months, including the US government deeming the technology an R&D priority, which was followed by a report that the Trump administration was in talks to accumulate equity stakes in D-Wave and its peers. D-Wave had outperformed rivals on this news, as this would have constituted a bigger shift in how the government feels about this annealing-centric quantum company relative to its peers, which focus on gate-based models. Back in May, Baratz told us he “couldn’t even get a foot in the door” with the US government, calling its focus on gate-based models “profoundly disappointing.”

However, that report of direct government investment in quantum computing stocks was quickly contradicted by separate reports.

Shares of the quantum computing company peaked at nearly $47 in mid-October, but slumped into the mid-$30 range ahead of this report as part of a broad pullback across many speculative pockets of the market.

More Markets

See all Markets
markets

CarMax plunges on weak preliminary sales results and the sudden firing of its CEO

CarMax shares are down more than 11% in premarket trading on Thursday following the sudden termination of its CEO, Bill Nash, who’d served as chief executive for nine years.

The announcement came as CarMax posted preliminary third-quarter results, including an expected comparable-store unit sales decrease of 8% to 12%.

“CarMax is the nation’s largest used car retailer because we have built a business that customers trust,” said CarMax Board Chair Tom Folliard, who has been named the company’s interim CEO. “However, our recent results do not reflect that potential and change is needed.”

Folliard previously served as CarMax’s CEO for 10 years until Nash succeeded him.

The leadership change comes as CarMax rival Carvana closes its unit sales gap quarter by quarter. Despite selling more used vehicles, CarMax’s market cap is less than a tenth of Carvana’s.

“CarMax is the nation’s largest used car retailer because we have built a business that customers trust,” said CarMax Board Chair Tom Folliard, who has been named the company’s interim CEO. “However, our recent results do not reflect that potential and change is needed.”

Folliard previously served as CarMax’s CEO for 10 years until Nash succeeded him.

The leadership change comes as CarMax rival Carvana closes its unit sales gap quarter by quarter. Despite selling more used vehicles, CarMax’s market cap is less than a tenth of Carvana’s.

markets

Oscar Health beats on adjusted EPS by a penny, CEO says it will “return to profitability” in 2026

Oscar Health rose in premarket trading after it reported earnings results that edged ahead of Wall Street expectations by a penny.

The company reported a loss per share of $0.53, compared to the $0.54 loss per share analysts polled by FactSet were penciling in. Oscar reported $2.92 billion in revenue, compared to $3.07 billion analysts expected.

Oscar CEO Mark Bertolini said in a statement that the company is “confident in our ability to expand margins and return to profitability in 2026.”

It also reported a medical loss ratio, a key metric that measures how much revenue from premiums is spent on providing care, of 88.5%, a slightly better result than the 88.8% the Street was expecting. Health insurance companies — particularly those that provide government-sponsored plans, like Oscar — have had a tumultuous year amid soaring medical costs.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.